[Genetic basis of subsequent malignant neoplasms]

Area of Science:

• Pediatric Oncology
• Cancer Genetics
• Genomics

Background:

• Subsequent malignant neoplasms (SMNs) are a significant late complication for childhood cancer survivors, affecting over 10% of long-term survivors.
• Germline mutations in cancer predisposition genes are increasingly recognized as a key risk factor for developing SMNs.
• Previous research suggests a link between polymorphisms in thiopurine pathway genes, such as TPMT, and SMN development post-acute lymphoblastic leukemia treatment.

Purpose of the Study:

• To highlight the importance of genetic predisposition in the development of SMNs in pediatric cancer survivors.
• To emphasize the need for individualized risk assessment for SMNs.
• To advocate for optimized therapeutic strategies based on individual SMN risk.

Main Methods:

• Comprehensive genomic analysis of a large cohort of long-term childhood cancer survivors.
• Identification and analysis of germline variants in cancer predisposition genes.
• Review of existing literature on genetic risk factors, including TP53 mutations and TPMT polymorphisms.

Main Results:

• Germline variants in cancer predisposition genes are correlated with a higher cumulative incidence of SMNs.
• TP53 gene mutations are identified as a specific risk factor for SMNs.
• Polymorphisms in thiopurine pathway genes (e.g., TPMT) may contribute to SMN development.

Conclusions:

• Genetic factors, particularly germline mutations, play a crucial role in the etiology of SMNs in childhood cancer survivors.
• Individualized risk stratification based on genetic profiling is essential for proactive management of late complications.
• Therapeutic approaches should be tailored to mitigate the specific SMN risks identified in each survivor.